BioSpace News Archive

FDA

Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery

Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics announced that the U.S. Food and Drug Administration has approved clobetasol propionate ophthalmic suspension 0.05%, for the treatment of post-operative inflammation and pain following ocular surgery.

March 4, 2024
·
4 min read
BioForest

BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences

BioLife Solutions, Inc. today announced that Roderick de Greef , Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.

March 4, 2024
·
1 min read
Drug Development

Molecular Templates, Inc. Provides Interim Update

Molecular Templates, Inc. today provided an update on its programs.

March 4, 2024
·
9 min read
BioMidwest

MediView Announces Study Results Demonstrating High Registration and Targeting Accuracy of Augmented Reality-Based Navigational Guidance System

MediView XR, Inc., a leading clinical augmented reality (AR) med-tech company, announced today study results of its XR90 AR-based surgical visualization and navigation system, published recently in the Journal of Medical Imaging.

March 4, 2024
·
3 min read
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 at 2:00 p.m. ET in Miami, Florida.

March 4, 2024
·
3 min read
Business

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024

Sera Prognostics Inc. today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, March 20, after the close of the market.

March 4, 2024
·
4 min read
Drug Development

Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy

Valo Health, Inc (Valo), a technology company focused on utilizing large scale data and artificial intelligence (AI) driven computation to discover and develop therapeutics, today announced full enrollment in the company’s Phase 2 Spectra clinical trial.

March 4, 2024
·
4 min read
Deals

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

Nektar Therapeutics today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the “PIPE”) for gross proceeds of $30 million, before deducting expenses.

March 4, 2024
·
4 min read
Genetown

Sarepta Therapeutics to Present at Upcoming Investor Conferences - March 4, 2024

Sarepta Therapeutics, Inc. today announced that senior management will participate in fireside chats at two upcoming investor conferences.

March 4, 2024
·
1 min read
Biotech Beach

Masimo to Present in 45th Annual Raymond James Institutional Investors Conference

Masimo (NASDAQ: MASI) today announced that its management will participate in the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5, 2024 at 3:25 p.m. Eastern Time.

March 4, 2024
·
3 min read